, Volume 60, Issue 3, pp 597–605

Treatment of Chlamydia trachomatis Infections in Pregnant Women

  • Joseph M. Miller
  • David H. Martin
Disease Management

DOI: 10.2165/00003495-200060030-00006

Cite this article as:
Miller, J.M. & Martin, D.H. Drugs (2000) 60: 597. doi:10.2165/00003495-200060030-00006


The intent of this article is to provide an overview of the epidemiology and pharmacotherapy, including cost analyses, of Chlamydia trachomatis infections in pregnant women. Chlamydia is a common sexually transmitted infection. For pregnant women, there are concerns both for the mother (post-partum endometritis, horizontal transmission) and the newborn (conjunctivitis, delayed pneumonia). Therapeutic options are restricted because of the fetus and include multi-day treatment with erythromycin, amoxicillin, clindamycin or single dose azithromycin. Clinical cure rates with these options are 86, 92, 93 and 95%, respectively.

Pharmacoeconomic analyses have been conducted to determine if the initial increase in acquisition cost of azithromycin (approximately 3-fold higher than erythromycin or amoxicillin) is offset by improvement in compliance and drug efficacy. Clindamycin has received little attention because of its expense (4-fold more than azithromycin). Analyses have been retrospective. As models incorporate more complications of failure to cure, azithromycin increasingly becomes more cost effective and is our recommended treatment.

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Joseph M. Miller
    • 1
  • David H. Martin
    • 2
  1. 1.Department of Obstetrics and GynecologyLouisiana State University Medical CenterNew OrleansUSA
  2. 2.Department of MedicineLouisiana State University Medical CenterNew OrleansUSA